Synthesis and Antimalarial Activity of 2-Phenyl-1,10-Phenanthroline Derivative Compounds
Abstract
To develop new potential antimalarial drugs of 2-phenyl-1,10-phenanthroline 5 derivatives from 8-aminoquinoline as startingmaterial were synthesized in good yields. The synthesis of 2-phenyl-1,10-phenanthroline 5 derivatives compoundswith 8-aminoquinoline 4 as starting material through three steps has been carried out. The first step of reactions is aldolcondensation of benzaldehyde 1 with acetaldehyde 2. The result of reactions is cinnamaldehyde 3 (92.14%) in the form ofyellow solid. The second step of reactions was synthesized of 2-phenyl-1,10-phenanthroline 5 (brown solid, 54.63%)through cyclization of 8-aminoquinoline 4 with cinnamaldehyde 3 compound. The third step of reactions is methylation andethylation of 2-phenyl-1,10-phenanthroline using dimethyl sulphate (DMS) and diethyl sulphate (DES) reagents that it wasrefluxed for 17 and 19 h, respectively. The results of reactions are (1)-N-methyl-9-phenyl-1,10-phenanthrolinium sulphate 6and (1)-N-ethyl-9-phenyl-1,10-phenanthrolinium sulphate 7 in yield from 90.62% and 89.70%, respectively. The results oftesting in vitro antiplasmodial activity at chloroquine-resistant Plasmodium falciparum FCR3 strain to 2-phenyl-1,10-phenanthroline 5 derivatives obtained that (1)-N-ethyl-9-phenyl-1,10-phenanthrolinium sulphate 7 compound has higherantimalarial activity (IC 50 :0.13 ± 0.02 μM) than antimalarial activity of (1)-N-methyl-9-phenyl-1,10-phenanthrolinium sulphate6 compound (IC 50 :0.25 ± 0.01 μM) and 2-phenyl-1,10-phenanthroline 5 compound (IC 50 :2.45 ± 0.09 μM). While, the resultsof testing in vitro antiplasmodial activity at chloroquine-resistant Plasmodium falciparum D10 strain to 2-phenyl-1,10-phenanthroline 5 derivatives obtained that (1)-N-methyl-9-phenyl-1,10-phenanthrolinium sulphate 6 compound has higherantimalarial activity (IC 50 :0.10± 0.04 μM) than antimalarial activity of (1)-N-ethyl-9-phenyl-1,10-phenanthrolinium sulphate7 (IC 50 :0.18 ± 0.01 μM) and 2-phenyl-1,10-phenanthroline 5 compound (IC 50 :0.55 ± 0.07 μM).
Keywords
Full Text:
PDFReferences
Basco, L.K., Ruggeri, C & Le Bras, J. 1994. Molecules Antipaladiques: Relations Structure-Activity. Edition Masson.
Bassi, P.U., Buratai, B.I & Kuchali, W. 2006. Effect of halofantrine administration on some liver and heart enzymes in healthy human volunteers. Afr J Biomed Res 9(1): 31–35.
Fidock, D.A., Rosenthal, P.J., Croft, S.L., Brun, R & Nwaka, S. 2004. Antimalarial drug discovery: efficacy models
for compound screening. Nature Rev 3(6): 509–520.
Fernández, A & Valdés, C. 2011. Acridine and acridinones:old and new structures with antimalarial activity. OMed Chem J 5: 11–20.
Hadanu, R., Mastjeh, S., Jumina., Mustofa., Wijayanti, M. A & Sholikhah, E.N. 2007. Synthesis and antiplasmodial activity testing of (1)-N-(4-methoxybenzyl)-1,10-phenanthrolinium bromide. Indo JChem 7(2): 197-201.
Karbwang, J. & Banchang, K.N. 1994.Clinical pharma-cokinetics of halofantrine. Clin Pharmacokinet 27: 104– 119.
Kayembe, J.S., Taba, K.M., Ntumba, K., Tshiongo, M.T.C & Kazadi, T.K. 2010. In vitro anti-malarial activity of 20 quinones isolated from four plants used by traditional healers in the Democratic Republic of Congo. J Med Plant Res 4(11): 991–994.
Molyneux, M.E., Taylor, T.E., Wirima, J.J & Borgstein, A. 1989. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 71(265): 441–459.
Mustofa., Yapi, A.D., Valentin, A & Tahir, I. 2003. In Vitro antiplasmodial activity of 1,10-phenanthroline derivatives and its quantitative structure-activity relationship. BIKed 35(2): 67–64.
Olumese, P. 2005. Epidemiology and surveillance: Changing the global picture of malaria myth or reality?. AcTrop 95(3): 265–269.
Rang, H.P., Dale, M.M., Ritter, J.M & Moore, P.K. 2003. Pharmacology, 5th ed, Edinburg: Churchill Livingstone.
Solikhah, E.N., Supargiono., Jumina., Wijayanti, M.A., Tahir, I., Hadanu, R & Mustofa. 2006. In vitro antiplasmodial activity and cytotoxicity of new (1)-N-alkyl and (1)-N-benzyl-1,10-phenantrolinium derivatives. Trop Med Public Health 36(6): 1072–1077.
Trager, W & Jensen, J.B. 1976. Human malaria parasites in continuous culture. Science 193(4254): 673–675.
Wensdorfer, W.H & Payne, D. 1991. The dynamics of drugs resistance in P. falciparum. Pharmac Ther 50: 95-121.
WHO. 2009. World Health Organization, Malaria Unit, Global malaria control. Bull. WHO 71(34): 281–284.
Widjayanti, M.A., Solikhah, E.N., Tahir, I., Hadanu, R., Jumina., Supargiono & Mustofa. 2006. Antiplasmodial activity and acute toxicity of N-alkyl- and N-benzyl-1,10-phenanthroline derivatives in mousa malaria model. J Health Sci 52(6): 794–799.
Yapi, A.D., Mustofa, M., Valantin, A., Chavignon, O., Teulade, J., Mallie, M., Chappat, J & Blace, Y. 2000. New potensial antimalarial agents: synthesis and biological activities of original diaza-analogs of phenanthrene. J Chem Pham Bull 48(12): 1886–1889.
Yapi, A.D., Valentin, A., Chezal, J.M., Chavignon, O., Chaillot, B., Gerhardt, R., Teulade, J.C & Blace, Y. 2006. In vitro and in vivo antimalarial activity of derivatives of 1,10-phenanthroline framework, Arch. Pharm. Chem Life Sci 339(4): 201–206.
DOI: http://dx.doi.org/10.31258/jnat.15.1.57-62
Refbacks
- There are currently no refbacks.
Copyright (c) 2014 Ruslin Hadanu, Mustofa, Nazudin
This work is licensed under a Creative Commons Attribution 4.0 International License.